Envision Pharma Group acquires artificial intelligence technology company OKRA.ai

Pivotal acquisition in Envision Pharma Group’s tech-enabled offerings provides clients with access to advanced AI to accelerate decision-making which optimizes their products’ path to market and ultimately supports the delivery of enhanced patient outcomes.

Envision Pharma Group acquires artificial intelligence technology company OKRA.ai

Feb 07, 2023
Envision Pharma Group acquires artificial intelligence technology company OKRA.ai Image

Envision Pharma Group (Envision), a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced today it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with services across commercialization, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.

OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and positive outcomes to clients in the life sciences industry.

“We are delighted to welcome OKRA.ai into the Envision family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly support patients in their journey to health and wellness.” 

Dr. Loubna Bouarfa, founder of OKRA.ai, will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining forces with Envision and to see the enormous opportunities for the growth of our combined expertise and solutions for clients in the life sciences industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life sciences industry. Our success will not only bring commercial benefit to clients, but lead to improved patient outcomes across the globe.” 

Based in the UK and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1400+ employees across four continents. 

Close

Envision Pharma Group hires leading industry executives Dominic Marasco and Gregory Carpenter to lead further expansion of the business and support growing customer demand

Join Envision Pharma Group at the 2023 European Meeting of ISMPP 

Envision Pharma Group is an exhibitor and elite sponsor at the 2023 European Meeting of ISMPP that is taking place from January 24–25 in London, UK. 

ISPOR Europe 2022 roundup

The onsite Envision team shares its key takeaways from ISPOR Europe 2022

Envision Pharma Group hires leading industry executives Dominic Marasco and Gregory Carpenter to lead further expansion of the business and support growing customer demand

Jan 31, 2023
Envision Pharma Group hires leading industry executives Dominic Marasco and Gregory Carpenter to lead further expansion of the business and support growing customer demand Image

Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A, technology-enabled solutions, and strategic consulting for the life sciences industry.

Dominic “Nick” Marasco has joined as Chief Commercial Officer of Envision Pharma Group, and member of the Executive Leadership Team. Nick is an experienced global commercial leader with nearly 30 years of pharmaceutical, biotech, and medical device industry experience. Having held several C-suite positions he has a proven track record of successfully launching and growing products and solutions with a focus on driving profitable revenue growth, building, and leading high-performing commercial organizations.

Nick will lead the development of Envision’s commercial-to-customer strategy while identifying new pathways to progression, with a focus on continuing its revenue growth and expanding its customer reach and solutions. He will help develop, lead, and reinforce Envision’s position as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions company. Another key part of his role is to implement a coordinated and integrated sales structure across Envision to reinforce its technology-enabled positioning. 

Before joining Envision, Nick served as Chief Commercial Officer of BioAgilytix, supporting three buyer-side acquisitions and integrations, as well as one sell-side sale of BioAgilytix to new private equity owners. Prior to BioAgilytix, he served as Executive Vice President, Global Business Development, Commercial at Syneos Health, where he led the overall strategic direction of the global business development team for the commercial division, both in the US and internationally. 

Nick was also previously Head of US Sales for the Neuroscience Business Unit at Amgen, and prior to that Global Commercial Head, Amgen Biosimilars. He has also held executive-level commercial and business development positions at Sandoz Biopharmaceuticals (a Novartis company) and IQVIA (formerly Quintiles).

Nick shares, “It is a distinct pleasure to join both Meg Heim and the entire team at Envision Pharma Group. Envision is a company that is experiencing phenomenal growth and high customer engagement and loyalty across each of the pillars of the organization and has continued to realize the growing demand of customer needs and advisory services. Even better, Envision has excelled at progressive innovation via services and technology to achieve a comprehensive solutions-oriented service platform. I am excited to join this dynamic team.”

Gregory “Greg” Carpenter joins Envision Pharma Group as Chief of Staff, CEO, and member of the Executive Leadership Team and brings with him a wealth of global experience and expertise. 

Greg has held several leadership roles in the pharmaceutical industry and positions spanning sales, marketing, medical, and transformation. His expertise covers areas of communications, strategic planning and implementation, coalition and consensus-building leadership development, omnichannel marketing, and change management.

Before joining Envision, Greg’s most recent role was leading a go-to-market transformation for the Sanofi US General Medicines team that included building an enterprise artificial intelligence (AI) solution, and helping the organization understand and embrace omnichannel marketing. 

Greg says, “I am delighted to join Envision Pharma Group and help carry out our mission of improving lives through a compelling combination of technology and services to enable clients to better serve patients. Through our expertise in scientific and commercialization strategy and solutions, medical affairs, and AI-driven technology solutions, Envision is helping our customers to excel in a rapidly changing healthcare environment.”

Meg Heim, Chief Executive Officer of Envision Pharma Group, adds, “I am so excited to welcome Nick and Greg to the Envision team. These new positions are critical to the fulfilment of our business expansion, mission, as well as being a commitment to our vision that enables us to execute upon our strategic plans.” 

Close

Join Envision Pharma Group at the 2023 European Meeting of ISMPP 

Dec 19, 2022
Join Envision Pharma Group at the 2023 European Meeting of ISMPP  Image

Envision Pharma Group is an exhibitor and elite sponsor at the 2023 European Meeting of ISMPP that is taking place from January 24–25 in London, UK.   

Meet the Envision team (Dawn LobbanCatherine ElliotLizzie PerdeauxHiroko EbinaAndy ShepherdLauren ManningStephen Craig, and Leif Måsvær) at booth #9 to discover how we connect our world-leading technology solutions with powerful scientific communications, driven by improving patient outcomes everywhere. At our booth, you can contribute your own scribe illustration in support of the ISMPP meeting theme “fueling creativity”! 

For a demonstration of how our technology solutions simplify collaborative reviews for research through services such as iEnvision® and doDOC®, or to find out more about our services – request a meeting with the on-site team at MeetMe@envisionpharma.com.  

We will be providing updates before, during, and after the event and will be sharing these through our social media page and this event web page, so check back soon. For the “What's on at ISMPP EU 2023” information, click the button below. 

Close

ISPOR Europe 2022 roundup

Nov 29, 2022
ISPOR Europe 2022 roundup Image

The Envision Value & Access team shares key takeaways from the ISPOR EU meeting in Vienna earlier this month. You can access the report below.

For more information on how we can support your value and access strategy and communications in an evolving world, contact the team at: value@envisionpharma.com

Access the report


Envision Value & Access unites market access strategy and scientific communications expertise. Collaboration and partnership are at the core of our philosophy, bringing together experts from across Envision Pharma Group, patient collaborators, and client partners to support access to innovative health technologies.

Close

Achieving Launch Excellence - Oncology

Article

The value of diverse patient representation and engagement in cancer treatment

Whitepaper

Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value

Leading global technology-enabled scientific communications company Envision Pharma Group is a platinum sponsor at ISPOR EU 2022, as well as an exhibitor.

Achieving Launch Excellence - Oncology

Nov 09, 2022
Achieving Launch Excellence - Oncology Image

Any new drug launch must overcome numerous obstacles in the pursuit of success

“Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc.” So how does this differ for a small and emerging biotech firm?”

In an article published earlier this year, Envision Pharma Group’s Rachel Shemer, along with Two Labs Angus Bromley and Kimberly Cash, discuss the advantages and challenges smaller companies face.

Close

The value of diverse patient representation and engagement in cancer treatment

Nov 02, 2022
The value of diverse patient representation and engagement in cancer treatment Image

Whitepaper

“To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy, and care over recent years, it is of crucial importance to ensure all patients with cancer have a role and an ongoing dialogue with the healthcare team.”

Ensuring all patients with cancer have a role and an ongoing dialogue with their healthcare team is crucial.

In a whitepaper published earlier this year Envision Pharma Group’s Rebecca Goldstein, PhD, CMPP, and 90TEN’s Mark Lakeram discuss the value of diverse patient representation and engagement in cancer treatment.

Close

Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value

Oct 13, 2022
Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value Image

Envision Value & Access is an exhibitor and platinum sponsor at ISPOR EU 2022. As an insight-driven strategic consulting partner for clients and with a full array of HEOR and access services, from the development of your HEOR strategy and RWE roadmap through to evidence generation and communication, we work across functions to develop, communicate, and capture the value of products through a coherent and integrated payer strategy to improve patient access and outcomes globally.

Come meet Suki Kandola, Joe Merkert, and other Envision Value & Access team members at ISPOR Europe 2022, Booth X2-210!
November 6-9; Vienna, Austria

Want to meet at a specific day and time at the event? Then send a message to: Value@envisionpharma.com

Envision Value & Access has the following posters presented at ISPOR Europe 2022:

  • “Deprivation and Access to Care Among Patients with Melanoma in the UK” 
    Vitaccess Ltd: Casey Quinn and Mark Larkin, Pfizer: Ira Jacobs, Envision Pharma Group: Suki Kandola and Karen E. Smoyer
     
  • “A Comparison of the Evolution of Payer Management Practices in Oncology in the United States, Germany, France, and the United Kingdom, Over the Past Five Years”
    Envision Pharma Group: Anne Runyan, Janice Yi, Mounika Bodagala, Milos Pavic, and Thomas Schoenwaelder
     
  • “Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations​”
    Envision Pharma Group: Sheli Goldstein, Anne Runyan, Joe Merkert, Thomas Schoenwaelder, and Milos Pavic
Close

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry

Collaboration capitalizes on Alucio’s flagship Beacon platform and Envision’s global leadership in medical strategy and healthcare communications

Envision Pharma Group appoints Head of Envision Value & Access

Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.

Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape

HCP demands for more responsive, coordinated engagement across the life sciences organization are driving MSLs to adopt a more agile and value-driven omnichannel approach

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry

Oct 06, 2022
Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry Image

Envision Pharma Group (Envision) and Alucio today announced a global partnership to power impactful, scientific exchange and deliver additional value for life science customers.

By combining Alucio’s innovative Beacon scientific exchange platform and technology with Envision’s extensive medical affairs experience and scientific content development expertise, a broader set of life science companies will have the ability to assemble, refine, and adapt their scientific content with ease. Beacon is a modern content activation and healthcare professional engagement platform built specifically for medical science liaisons, medical affairs professionals, and market access teams.

Through this collaboration, Envision will provide strategic, insight-driven communications expertise with agile content development approaches to assist medical affairs and market access teams in taking full advantage of the Beacon platform and future Alucio technology products.

More broadly, this global partnership has the potential to transform current industry standards in stakeholder engagement by redefining best practice content development processes and leveraging technology to create powerful, personalized scientific exchanges. Through a user-centric approach, the companies will seek to enhance and integrate technology solutions that deliver real-time data and analytics to inform strategy and aid customer decision-making.

“Envision is a recognized, global leader within the medical affairs space. We are very excited about the potential of this partnership to bring the benefits of our modern scientific exchange platform to an even broader network and establish best practice in the context of content development, deployment, and engagement,” said Dave Gulezian, Alucio Co-Founder and Chief Executive Officer. “We also look forward to collaborating to identify new opportunities to address emerging customer needs.”

Envision’s Chief Executive Officer, Meg Heim, added, “We have been impressed with what Alucio has built with Beacon and the momentum they have generated within the medical affairs space. We’re equally excited to align our medical strategy, agile content development, and communications expertise with Alucio’s technology capabilities to further enhance our customers’ stakeholder engagement through a personalized, omnichannel approach.”

 

 

Close

Envision Pharma Group appoints Head of Envision Value & Access

Oct 03, 2022
Envision Pharma Group appoints Head of Envision Value & Access Image

Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.

Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.

Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”

Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”

Close

Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape

Sep 27, 2022
Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape Image

Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, and Aktana, the leader in intelligent customer engagement for the life sciences industry, have announced a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange.

By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address healthcare professionals’ (HCPs) demands for personalized, scientifically relevant content, and coordinated omnichannel engagement.

Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equipping commercial teams with technology to synthesize data and coordinate interactions across channels, medical affairs organizations still largely lack the right tools to navigate the dual challenges of information overwhelm and decreasing HCP access. 

“MSLs are in a challenging position, learning to balance traditional and modern digital strategies to engage with physicians in an environment where they are asked to respond to questions faster and more frequently,” said Derek Choy, president of Aktana. “With Envision, we can help MSLs by optimizing their HCP engagements to be more relevant, coordinated, and tailored to their individual needs, whether digital or in-person.”

Together, Envision and Aktana will provide medical affairs teams with streamlined, tailored solutions that incorporate Envision’s industry-leading scientific expertise with Aktana’s intelligence platform, which is fueled by a range of integrated data sources and learns from every prior interaction. The partnership arms MSLs with quick, reliable access to the latest scientific information that’s relevant to each HCP, paired with data-driven insights on how, when, and where to deliver that information for optimal customer engagement. 

“Like us, Aktana has a long history of helping life sciences companies of all sizes break down data silos, connect internal teams, and generate insights to improve interactions with HCPs,” said Paul Archer, Chief Commercial Strategy Officer at Envision. “Together, we will focus on guiding medical affairs teams to build, deploy, and refine their omnichannel strategies so MSLs can deliver value to HCPs when they need it most for improved patient outcomes.” 

Archer continued, “We look forward to a long-term partnership with Aktana, as we take the next steps toward our combined vision for a powerful solution that incorporates all touchpoints across the HCP journey.”

Close

Envision Pharma Group appoints new CEO

Meg Heim named as its new Chief Executive Officer

Envision partners with Vitaccess for patient engagement webinar

Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform

Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules

Envision Pharma Group appoints new CEO

Sep 21, 2022
Envision Pharma Group appoints new CEO Image

Envision Pharma Group is pleased to announce the appointment of Meg Heim as its new Chief Executive Officer. Meg is an accomplished business leader with strong leadership experience, and an established reputation within Pharmaceutical, Medical Device and Health Technology markets. Throughout her career she has championed the professionalism of medical affairs and the innovations that improve patient experience.

Working closely with a strong and experienced Executive Leadership Team, Meg will be responsible for delivering an ambitious five-year plan that will reinforce Envision as the global leader in scientific and commercialization strategy and solutions; medical affairs; and lifecycle planning enabled by leading technology solutions and world-class people.

Meg joins Envision at a pivotal moment, with Group performance accelerating as it continues to deliver a compelling combination of technology and services to clients. Envision’s strategy and innovation has ensured the company continues to serve and anticipate its clients’ evolving needs. Meg replaces David Thompson, who steps down as CEO to pursue other opportunities, including in the not-for-profit sector at a cancer charity, after more than six years with Envision Pharma Group and over 25 years in the industry.

Brian Hepburn Executive Co-Chair of Envision Pharma Group said: “I am truly excited by the appointment of Meg as our new Chief Executive Officer. Meg has an established track record within the healthcare industry and brings with her a deep understanding of medical affairs which will be highly complementary to the existing expertise within the business. This is an exciting time for Envision as we continue to accelerate innovation and work towards our vision of improving lives through the power of our technology and expertise.”

Meg said: “I am energized to be joining Envision Pharma Group at such an important time in the industry. I see a clear opportunity for further growth building off established and new opportunities in the sector. The company has an exceptional team and client base, and I am looking forward to spending time with our people, our clients, and other key partners.”

Close

Envision partners with Vitaccess for patient engagement webinar

Jun 28, 2022
Envision partners with Vitaccess for patient engagement webinar Image

Following the announcement in March of our Vitaccess partnership that is designed to power evidence generation for the biopharmaceutical industry, we are thrilled to be collaborating with Vitaccess on its “Keeping it real” webinar series.

On July 20, Envision’s Dawn Lobban, Global Lead, Patient Partnerships from Envision the Patient, will join Dr. Catherine Bottomley, Chief Scientific Officer from Vitaccess, to discuss patient engagement in the publication of real-world evidence (RWE). Secure your seat here in order to listen to two engaging and passionate speakers cover patient engagement and RWE.

Close

Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform

Jun 07, 2022
Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform Image

Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) today announced Library, Datavision, and Scientific Communication Platform (SCP) modules will now feature Smart Citations from scite, an award-winning tool that helps students and researchers discover and understand research findings better.

Fully integrated into the publication details held within Library, Datavision, and SCP modules, Smart Citation badges provide regularly updated, at-a-glance views of how research has been cited and permits click-through access to the scite website for more detailed information on the article. This new functionality sits alongside and enhances the existing article-level metrics provided in iEnvision through integrations with Altmetric and Scopus.

Russell Traynor, Envision’s Global Head, iEnvision Platform Strategy, and former chair of the International Society of Medical Publication Professionals, said, “We are excited to announce this collaboration and hope that the addition of Smart Citations to Library, Datavision, and SCP will provide additional insights and value to the users of our solutions.”

Dr. Josh Nicholson, Chief Executive Officer of scite, added, “We’re very happy to be working with Envision to provide a powerful integration between the two platforms. Smart Citations are already used by various pharmaceutical companies and communications agencies and we’re happy to surface them in Library for a more streamlined workflow.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com

About scite

scite is a Brooklyn-based start-up that helps researchers discover and evaluate scientific articles better through Smart Citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from around the world and is funded in part by the National Science Foundation and the National Institute of Drug Abuse of the National Institutes of Health. Learn more at: scite.ai

About iEnvision Library

Library, built on the iEnvision medical project management platform, serves as a central repository for the enterprise-wide storage and sharing of final, approved scientific and medical materials such as publications and slide decks. Embedding Smart Citation in Library allows an at-a-glance view of the total number of times a paper has been cited and the context of these citations. Learn more at: www.envisionpharmagroup.com/technology/ienvision-library

About iEnvision Datavision®

The iEnvision Datavision module is designed to drive the compliant and efficient management of scientific and medical publications. With role-specific dashboards, publication managers can access the detailed information needed to start and manage publications. Containing built-in checklists and system validation, it ensures publications comply with Good Publication Practice and the International Committee of Medical Journal Editors (ICMJE) requirements. Learn more at: www.envisionpharmagroup.com/technology/datavision

About iEnvision Scientific Communication Platform

iEnvision’s SCP is a centralized medical affairs solution, linking key scientific themes and statements to product-related assets such as publications, slides, and videos. The common template of SCP themes, key statements, and supporting statements maintains simple user navigation and a standardized approach to the formatting and development of SCPs – with a lexicon designed to ensure a consistent use of language that includes preferred and prohibited terms. Learn more at: www.envisionpharmagroup.com/technology/scientific-communication-platform-module

Close